It's made such a difference and gives me more time to live my life
For decades, receiving life-sustaining cancer immunotherapy meant surrendering hours to hospital chairs and intravenous lines — a quiet tax on the time of the already burdened. Beginning this month, the NHS is rolling out an injectable form of Keytruda, one of the world's most widely used cancer drugs, reducing administration from over an hour to mere minutes for roughly 14,000 patients in England each year. The medicine itself has not changed, only the way it reaches the body — yet in that small technical shift lives a larger human truth: that how we deliver care shapes the experience of living with illness as profoundly as the treatment itself.
- Thousands of cancer patients have spent years surrendering hours each visit to intravenous infusions — time that accumulates into exhaustion and lost living.
- The NHS is now rolling out a ready-to-use injectable form of Keytruda that cuts administration from over sixty minutes to one or two, creating immediate pressure on hospitals to adapt their delivery models.
- With 14,000 patients annually across 14 cancer types in transition, chemotherapy units face both an operational opportunity and a logistical challenge in shifting established clinical routines.
- Freed capacity in hospital infusion suites is already prompting NHS planners to consider moving treatment into community settings — GP surgeries and local clinics — easing strain on overstretched oncology wards.
- The change arrives with a strategic undertone: Keytruda's patents expire between 2028 and 2031, making this injectable rollout a window to extend the drug's reach and efficiency before cheaper generics reshape the market.
Shirley Xerxes, 86, arrived at Mount Vernon Cancer Centre expecting to spend the better part of an hour in a treatment chair. She was done in minutes. The medicine was the same — Keytruda, the immunotherapy she had been receiving for years — but it arrived differently now, as a simple injection rather than a slow intravenous drip. She got her afternoon back. She got her garden back.
From this month, that experience becomes available to thousands. Keytruda — also known as pembrolizumab — has been used in the NHS since 2015, but only as an infusion requiring sterile pharmacy preparation and a cannula feeding medication slowly into the vein. The new injectable form arrives ready to use, administered in one to two minutes every three or six weeks depending on diagnosis. Around 14,000 patients in England begin Keytruda treatment each year, across 14 cancer types including lung, breast, and cervical. The drug works by stripping away the molecular camouflage that tumours use to hide from the immune system, and has become the world's best-selling prescription medicine, generating $30 billion in global sales in 2025 alone.
The personal relief is real and immediate — hours spent in hospital chairs, week after week, represent more than inconvenience; they are time taken from life. But the systemic implications are equally significant. Faster treatment frees chemotherapy units, opens staff capacity, and — according to NHS England's national clinical director for cancer, Prof Peter Johnson — could eventually allow treatment to migrate out of hospitals entirely and into community settings closer to patients' homes.
The NHS has not disclosed the price negotiated with manufacturer Merck Sharp & Dohme, though the cost is understood to be broadly equivalent to the infusion version. The savings lie in efficiency and freed hospital capacity rather than a cheaper drug. With Keytruda's patents set to expire in 2028 in the US and 2031 in Europe, the injectable rollout also represents a strategic window — a way to deepen the drug's reach within the health service before generic alternatives enter the market.
For patients like Xerxes, the arithmetic is simpler than any of that. Minutes instead of hours. Life, returned in small but meaningful increments.
Shirley Xerxes, 86, sat down in a chair at Mount Vernon Cancer Centre near Watford expecting to spend the better part of an hour there. Instead, she was done in minutes. The difference between what she experienced and what she had endured for years was the difference between an intravenous drip snaking into her arm and a simple injection. It was, she said later, transformative—not because the medicine changed, but because the delivery did. She got her afternoon back. She got her garden back.
Starting this month, thousands of cancer patients across England will have access to the same shift. Keytruda, one of the world's most prescribed cancer drugs, is being rolled out in a new injectable form that cuts hospital administration time from over an hour down to either one or two minutes, depending on the dosing schedule. The drug itself—also called pembrolizumab—has been used in the NHS since 2015, but only as an intravenous infusion, a process that required pharmacy teams to prepare the medication under sterile conditions and feed it slowly into patients' veins through a cannula. The new version arrives as a ready-to-use injection, administered either every three weeks or every six weeks based on individual diagnosis.
The scale of the shift is substantial. About 14,000 cancer patients in England begin treatment with Keytruda each year. Most of them are expected to transition to the injectable version. The drug is approved to treat 14 different cancer types in the UK—lung, breast, cervical, head and neck, and others—making it one of the most widely used immunotherapies in the country. Keytruda works by blocking the proteins that cancer cells use to hide from the immune system, essentially removing the invisibility cloak that allows tumors to evade the body's natural defenses. Since its approval, it has become the world's best-selling prescription medicine, with global sales reaching $30 billion in 2025 alone.
For patients, the benefit is immediate and personal. An hour or more spent in a hospital chair, week after week, month after month, accumulates into something larger than inconvenience. It is exhaustion. It is time stolen from life. Prof Peter Johnson, NHS England's national clinical director for cancer, framed it differently but with the same weight: managing cancer treatment and regular hospital trips is genuinely draining. Cutting that burden matters. But the implications extend beyond individual relief. Faster injections mean chemotherapy units free up space. They mean staff time opens up for other patients. They mean, Johnson suggested, that treatment could eventually move out of hospitals altogether and into community settings—GP surgeries, local clinics, places closer to home.
The NHS did not disclose the price it negotiated with Merck Sharp & Dohme, the American pharmaceutical company that manufactures Keytruda. The deal is confidential. What is known is that the health service will pay roughly the same amount for both the infusion and the injection versions, meaning the cost savings come not from a cheaper drug but from the efficiency of delivery and the freed-up hospital capacity. That matters because Keytruda's patent protection is finite. The original formulation's patents expire in 2028 in the United States and 2031 in Europe, at which point generic manufacturers can produce cheaper copies. The injectable version, then, represents a window—a way to maximize the drug's utility and reach within the NHS before the landscape shifts.
For Xerxes and patients like her, the calculus is simpler. She trades an hour in a hospital chair for minutes. She gains time. She gains her life back, piece by piece, week by week. That is the human arithmetic of this change, and it is the one that matters most.
Citações Notáveis
Managing cancer treatment and regular hospital trips can be really exhausting. If we can do this in a much shorter period of time, it frees up space in our chemotherapy units and means we can start thinking about giving treatment in the community and away from hospitals.— Prof Peter Johnson, NHS England's national clinical director for cancer
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that this is an injection instead of an infusion? Isn't it the same drug doing the same work?
It's the same drug, yes, but time is not abstract for someone receiving cancer treatment. An hour in a hospital chair, every few weeks, for months—that's not just inconvenience. That's your life on hold. An injection takes two minutes. You get your afternoon back.
But surely the NHS cares more about the hospital capacity angle than patient comfort?
Both matter, and they're connected. When you free up chemotherapy chairs and nursing time, you're not just being efficient—you're saying to patients: we can see more of you, faster, and we can do it closer to home. That's a real shift in how cancer care could work.
The article mentions patents expiring in 2028 and 2031. Why is that relevant now?
Because once generics arrive, this drug becomes cheaper but also more commodified. Right now, while Merck still has exclusivity, the NHS is maximizing what Keytruda can do—getting it to more patients in a better form. It's a window.
Do we know if patients actually prefer the injection, or is this just faster?
Xerxes preferred it. She said it gave her more time to live her life. But the preference isn't really about the needle versus the drip—it's about reclaiming hours. That's what people want back.